title: Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.
abstract: Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The good oral bioavailability and broad antimicrobial spectrum of activity, including antipseudomonal properties, make this class of antimicrobial attractive. We review the evidence assessing the use of fluoroquinolones in the context of preventing and eradicating early lung infection and in managing chronic lung infection and pulmonary exacerbations. The safety of fluoroquinolones and the use of newer agents in the class are also discussed.
authors.affiliation: Division of Child Health, University of Nottingham, Queens Medical Centre, Nottingham, UK. matthew.hurley@nottingham.ac.uk
authors.forename: Matthew
authors.initials: M
authors.lastname: Hurley
authors.forename: Alan
authors.initials: A
authors.lastname: Smyth
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D001682:Biological Availability; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000382:microbiology; D024841:Fluoroquinolones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones